Microbot begins U.S. launch of Liberty endovascular robot

Microbot Medical has begun the full U.S. market release of its Liberty endovascular robotic system. The launch was announced at the Society of Interventional Radiology annual meeting in Toronto.

Liberty is an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The company said the device is designed for vascular navigation while aiming to reduce radiation exposure and physical strain for interventional teams.

Commercial use has included prostate artery embolization, uterine fibroid embolization, genicular artery embolization, Y-90 mapping and delivery, and peripheral arterial interventions, according to Microbot.

The full release follows a limited market release that began in late 2025. Microbot said that early adoption included use by U.S. healthcare systems and demonstrated scalability across endovascular procedures.

To support the launch, the company expanded its U.S. sales reach from 4 to 8 territories. It plans to reach 12 territories by the end of 2026.

FDA granted 510(k) clearance for Liberty in September 2025. The clearance allowed Microbot to begin U.S. commercialization of the device for peripheral endovascular procedures.